臨床検査54巻10号

2010年10月発行

今月の主題 ファーマコゲノミクス 各論

精神神経疾患領域におけるファーマコゲノミクス

著者： 武田雅俊¹ 橋本亮太¹

所属機関： ¹大阪大学大学院医学系研究科情報統合医学講座精神医学教室

ページ範囲：P.1151 - P.1157

　向精神薬の代謝にかかわる酵素群の中でもチトクロムP450酵素群(CYP P450)は，重要である．向精神薬の60～80％は，CYP1A2，2B6，2C8/9，2C19，2D6，3A4により代謝され，特にCYP3A4は半数以上の薬剤の代謝に関与する．CYP2D6，CYP2C9，CYP2C19には薬物代謝能に違いを呈する遺伝子多型が知られており，完全代謝型(EM)，中間代謝型(IM)，不全代謝型(PM)，超急速代謝型(UM)に区分される．このような薬物動態にかかわる遺伝子群だけでなく，向精神薬の薬効・副作用には多くの遺伝子群が関与する．それぞれの精神疾患の病態にかかわる遺伝子群がその候補ととして検討されているが，いまだ十分には整理されていない．

参考文献

1) Cacabelos R:Pharmacogenomics in Alzheimer's disease. Meth Mol Biol　448：213-357，2008

2) Cacabelos R, Takeda M:Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer's disease. Drugs Future　31(Suppl B)：5-146，2006

3) Cacabelos R:Pharmacogenomic biomarkers in neuropsychiatry:The path to personalized medicine in mental disorders. In:The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes. Ritsner MS (eds), Springer, Netherlands，pp3-63，2009

4) Cacabelos R:Pharmacogenomics and therapeutic strategies for dementia. Expert Rev Mol Diag　9：567-611，2009

5) Xie HG, Kim RB, Wood AJ, et al:Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharm Toxicol　41：815-850，2001

6) Madan A, Graham RA, Carroll KM, et al:Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos　31：421-431，2003

7) Hedlund E, Gustafsson JA, Warner M:Cytochrome P450 in the brain:a review. Curr Drug Metabol　2：245-263，2001

8) Funae Y, Kishimoto W, Cho T, et al:CYP2D in the brain. Drug Metab Pharmacokin　18：337-349，2003

9) Kobylecki CJ, Jakobsen KD, Hansen T, et al:CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients:a retrospective matched case-control study. Neuropsychobiology　59：222-226，2009

10) Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.cypalleles.ki.se/(2009年9月9日現在)

11) Yokoi T, Kosaka Y, Chida M, et al:A new C YP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics　6：395-401，1996

12) Kubota T, Yamaura Y, Ohkawa N, et al:Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan demethylation in different CYP2D6 genotype. Br J Clin Pharmacol　50：31-34，2000

13) Kang RH, Jung SM, Kim KA, et al:Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J Clin Psychopharmacol　29：272-277，2009

10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. Hum Psychopharmacol　24：301-308，2009

15) Fleeman N, McLeod C, Bagust A, et al:The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics:a systematic review and economic evaluation. Health Technol Assess　14：1-182，2010

16) Collier DA, Stober G, Li T, et al:A novel functional polymorphism within the promoter of the serotonin transporter gene:possible role in susceptibility to affective disorders. Molecular Psychiatry　1：453-450，1996

17) Serretti A, Kato M, De Ronchi D, et al:Meta-analysis of serotonin transprter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry　12，247-257，2007

18) Bocchio-Chiavetto L, Miniussi C, Zanardini R, et al:5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neurosci Lett　437：130-134，2008

19) Ikeda M, Tomita Y, Mouri A, et al:Identification of Novel Candidate Genes for Treatment Response to Risperidone and Susceptibility for Schizophrenia:Integrated Analysis Among Pharmacogenomics, Mouse Expression, and Genetic Case-Control Association Approaches. Biol Psychiatry　67：263-269，2010

20) Iwahashi K, Murayama O, Aoki J, et al:Influence of serotonin (5-HT) 2A-receptor and transporter (5HTT) gene polymorphism upon the effect of olanzapine Nihon Shinkei Seishin Yakurigaku Zasshi　29：141-144，2009

21) Wei Z, Wang L, Xuan J, et al:Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry　33：547-551，2009

22) Chen SF, Shen YC, Chen CH:Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Prog Neuropsychopharmacol Biol Psychiatry　33：470-474，2009

23) Chen SF, Shen YC, Chen CH:HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology (Berl)　205：285-292，2009

24) Zuo L, Luo X, Krystal JH, et al:The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet Genomics　19：437-446，2009

25) Cashman JR, Zhang J, Nelson MR, et al:Analysis of flavin-containing monooxygenase 3 genotype data in populations administered the anti-schizophrenia agent olanzapine. Drug Metab Lett　2：100-114，2008

26) Gupta M, Bhatnagar P, Grover S, et al:Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics　10：385-397，2009

27) Herken H, Erdal M, Aydin N, et al:The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol　28：515-519，2009

28) Ujike H, Nomura A, Morita Y, et al:Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients:a cohort study. J Clin Psychiatry　69：1416-1422，2008

29) Basile VS, Masellis M, McIntyre RS, et al:Genetic dissection of atypical antipsychotic-induced weight gain:novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry　62(Suppl23)：45-66，2001

30) Gunes A, Melkersson KI, Scordo MG, et al:Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol　29：65-68，2009

31) Gregoor JG, van der Weide J, Mulder H, et al:Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J Clin Psychopharmacol　29：21-25，2009